Search
Immunome Inc
IMNMAdd to Watchlist
24.240USD
-1.510-5.86%
Close 09-23 16:00（ET）
2.75BMarket Cap
LossP/E TTM
Immunome Inc (IMNM) Stock Price Target & Forecast
Analyst Rating
Based on 14 analysts giving stock ratings to Immunome Inc in the past month.
Buy
3 Strong Buy
11 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
35.769USD+38.91%
IMNM Analyst Recommendation Trends
In the current month, IMNM has received 11 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. IMNM average Analyst price target in the last month is 35.769.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
3
3
3
4
4
4
4
4
11
11
11
11
10
10
10
9
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
14
14
14
15
14
14
14
13
IMNM Analyst Rating for Peer Comparison
Updated: Sep 23, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
1
0
28
Ionis Pharmaceuticals Inc
IONS
6
14
6
0
0
26
argenx SE
ARGX
10
13
3
0
0
26
IQVIA Holdings Inc
IQV
8
12
4
0
0
24
Insmed Inc
INSM
7
17
0
0
0
24
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
CRISPR Therapeutics AG
CRSP
4
8
10
0
0
22
Revolution Medicines Inc
RVMD
8
13
1
0
0
22
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Tempus AI Inc
TEM
5
6
7
1
1
20
Financial Forecasting
Based on analysts' estimates, IMNM EPS is projected to reach -0.619 in FY2026Q3, following reported EPS of -0.646 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.60
-0.56
-0.52
-0.62
-0.64
Actual
-0.74
-0.48
-0.65
--
--
Surprise
-22.31%
+15.37%
-23.64%
--
--
FAQs
What is Immunome Inc's expected revenue for the next quarter?
Immunome Inc's expected revenue is 181.82K.
What is Immunome Inc's price target?
Analysts forecast that Immunome Inc's price target is USD 35.77, with the highest forecast at USD 40.00 and the lowest forecast at USD 30.00.
How have Immunome IncIMNM's recent earnings per share performed?
The market expectation was USD -0.65, while Immunome IncIMNM's earnings per share (EPS) for the previous quarter was USD -0.48. EPS for the next quarter is expected at USD -0.62.
What is the analyst rating for Immunome Inc?
Based on the ratings of Immunome Inc's stock from 14 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.